JophTh.com
About JophTh.com
Jerini Ophthalmic, Inc. is a wholly-owned, independent US subsidiary of the German company, Jerini, AG (FSE:JI4). The Company began operations in March 2007 to focus on the rapid development of novel, extended-release therapeutics for unmet medical needs in ophthalmology. Using Jerini AG's Peptides-to-Drugs (P2D) technology platform, Jerini Ophthalmic is now responsible for developing compounds targeting pathways believed to be involved in several sight-threatening ophthalmic indications.
